Trials / Terminated
TerminatedNCT04951492
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
OUTLINE: Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up to 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | Given PO |
Timeline
- Start date
- 2022-11-09
- Primary completion
- 2023-10-15
- Completion
- 2023-10-15
- First posted
- 2021-07-06
- Last updated
- 2025-01-01
- Results posted
- 2025-01-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04951492. Inclusion in this directory is not an endorsement.